US Patent 8410131 Cancer treatment
Patent 8410131 was granted and assigned to Novartis on April, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 23 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+152 characters)
Article
Patent abstract
Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Heidi Lane0
Jeanette Marjorie Wood0
Terence O'Reilly0
Edits on 28 Jun, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08410131 Cancer treatment US Patent 8410131 Cancer treatment
Infobox
Patent Number
084101310
Patent Number
84101310
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084101310
Date of Patent
April 2, 2013
0Patent Application Number
104685200
Date Filed
February 18, 2002
0Patent Primary Examiner
Edits on 16 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08410131 Cancer treatment
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08410131
Date of patent
April 2, 2013
Patent application number
10468520
Date Filed
February 18, 2002
Patent primary examiner
Find more entities like US Patent 8410131 Cancer treatment
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
